- Home
- People
- CLINUVEL news
Nasdaq TradeTalks Interview
CLINUVEL’s Managing Director, Dr Philippe Wolgen, speaks with Jill Malandrino on Nasdaq TradeTalks, 26 October 2021.R&DDr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.Finance & investingInsider Insights III: Willem Blijdorp, Challenges & the Future
In the third and final part of this Insider Insights series, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer discuss navigating contemporary challenges within a public company...Finance & investingInsider Insights II: Willem Blijdorp, CLINUVEL’s Products, People & Social Purpose
In this second of three Insider Insights, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer explore the products, people and social purpose of the ASX-listed Group (CUV).
- R&D
- R&D
Dr Pilar Bilbao – Update on CLINUVEL’s Stroke Program
In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial...R&DDr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.R&DUnderstanding the effects of stroke
CLINUVEL has today announced that its drug afamelanotide was well tolerated by the first three arterial ischaemic stroke (AIS) patients enrolled in a world first clinical trial (CUV801). Watch our new video explaining the pathology and treatment of stroke.R&DHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay.  However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...R&DHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting 2022
On October 26th 2022 CLINUVEL PHARMACEUTICALS held its 2022 Annual General MeetingCLINUVEL newsCLINUVEL Investor Webinar on FY2022 financial results
In an investor and analyst webinar hosted by CLINUVEL, Mr Malcolm Bull, Head of Investor Relations, is joined by Mr Darren Keamy, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, in discussing the financial results for the year ended 30 June 2022 and the Company’s plans for FY2023 and beyond.CLINUVEL newsA CLINUVEL Webcast on Market Position, Financial Management and Growth
In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.CLINUVEL newsOperations Update I – 2022 Financial Results Webinar
CLINUVEL’s Chief Financial Officer, Darren Keamy, and Director of Global Operations, Lachlan Hay, discuss the financial results for the half year ended 31 December 2021, the Company’s multi-pronged growth and expansion strategy and the activities of the Pharmaceuticals and Healthcare Solutions Divisions.